FDA Approved Isatuximab-irfc for Multiple Myeloma
The FDA authorized the subcutaneous injection drug for use alongside a specialized on-body delivery system in July 2026.
Updated on Sept. 30, 2026 in Cancer
In July 2026, the FDA granted approval for isatuximab-irfc, a treatment indicated for the management of multiple myeloma. This regulatory decision specifically authorizes the drug for subcutaneous administration via the CirCLIQ on-body delivery system.
Why it matters
The approval provides patients and healthcare providers with a new delivery method for managing multiple myeloma. This milestone expands the available options for patients requiring targeted therapeutic interventions for this condition.
The FDA-approved treatment involves the use of the CirCLIQ on-body delivery system to administer isatuximab-irfc via subcutaneous injection. This authorization establishes a new clinical standard for delivering this specific myeloma therapy.
The players
Food and Drug Administration
The agency is the federal regulatory body responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.
The details
The newly approved method utilizes the CirCLIQ on-body delivery system to simplify the subcutaneous administration of isatuximab-irfc. This integration is designed to streamline the management of multiple myeloma by offering a more controlled delivery process.
Timeline
The FDA approved the subcutaneous injection drug in July 2026.
Health Landscape
This development aligns with the broader evolution toward integrated drug-device technology in cancer treatment. It reflects a shift in medical science toward more patient-centric administration methods for chronic disease management.
Patients diagnosed with multiple myeloma may now have access to a more convenient subcutaneous delivery option. This change could potentially reduce the time spent in clinical settings by utilizing the on-body delivery system.
The takeaway
The introduction of the CirCLIQ system highlights the ongoing trend of combining pharmacological treatments with wearable delivery hardware. Patients should consult with their oncologists to determine if this new administration method is appropriate for their specific care plan.
Further reading
For more information on recent advancements, visit the Cancer section.
Source note: This article includes information reported by OncLive.
